167 related articles for article (PubMed ID: 20005261)
1. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.
Asmar M; Højberg PV; Deacon CF; Hare K; Holst JJ; Madsbad S
Regul Pept; 2010 Feb; 160(1-3):175-80. PubMed ID: 20005261
[TBL] [Abstract][Full Text] [Related]
2. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
3. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
4. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
6. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
7. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
8. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses.
Rijkelijkhuizen JM; McQuarrie K; Girman CJ; Stein PP; Mari A; Holst JJ; Nijpels G; Dekker JM
Metabolism; 2010 Apr; 59(4):502-11. PubMed ID: 19846181
[TBL] [Abstract][Full Text] [Related]
9. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
10. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
11. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
12. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
14. Increased secretion and expression of amylin in spontaneously diabetic Goto-Kakizaki rats treated with rhGLP-1 (7-36).
Weng HB; Gu Q; Liu M; Cheng NN; Li D; Gao X
Acta Pharmacol Sin; 2008 May; 29(5):573-9. PubMed ID: 18430365
[TBL] [Abstract][Full Text] [Related]
15. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
16. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
17. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection.
Ekholm E; Shaat N; Holst JJ
Acta Diabetol; 2012 Oct; 49(5):349-54. PubMed ID: 21761282
[TBL] [Abstract][Full Text] [Related]
18. Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes.
Kaas A; Andersen ML; Fredheim S; Hougaard P; Buschard K; Petersen JS; de Beaufort C; Robertson KJ; Hansen L; Mortensen HB; Nielsen LB;
Pediatr Diabetes; 2012 Feb; 13(1):51-8. PubMed ID: 22118630
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Yang SJ; Choi JM; Kim L; Kim BJ; Sohn JH; Kim WJ; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW; Park CY
Biochem Biophys Res Commun; 2011 Apr; 407(1):153-7. PubMed ID: 21371430
[TBL] [Abstract][Full Text] [Related]
20. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
